go to main content
Radboudumc and partners Spin-off companies Aiosyn

About Aiosyn

Our solution helps pathologists to deliver faster and better pathological examinations anywhere in the world, anytime.

read more

About Aiosyn

AI-Powered Medicine

At the very core of our technology, we employ a successful form of machine learning called deep learning (a.k.a. artificial neural networks). These models are able to discern between normal and abnormal tissue patterns with unprecedented accuracy, accelerating and improving the medical workflow.

Clinical Diagnostics

We provide several solutions for clinical diagnostics that reduce workflow inefficiencies by streamlining the process of pathological examination, improving its overall quality, and reducing its cost.

Our current product offer focuses on breast and prostate cancer diagnosis, and we are quickly expanding it to applications involving colorectal, lung, and kidney tissue.

Life Sciences

We have designed specific solutions for the Life Sciences industry in order to identify novel pathology-based biomarkers that can accelerate drug development.

We offer a highly interoperable platform (cloud or on-premise), with a focus on ISO-13485 certification, competitively priced, and ready to accommodate any size of workload at global scale.

Aiosyn details

  • CEO: Patrick de Boer
  • Affiliated department: Pathology
  • Researcher: Jeroen van der Laak
  • Year of incorporation: 2021
Aiosyn website

News

Boosting the startup ecosystem in Nijmegen!

22 June 2023

TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.

Aiosyn raises EUR 2 million to develop AI-powered algorithms to support pathologists with clinical diagnostics

21 December 2022

Nijmegen, the Netherlands – Aiosyn is developing a diagnostics platform that uses artificial intelligence to support pathologists with more accurate and efficient clinical diagnostics. 

Aiosyn selected as finalist for OostNL's Startversneller vote now!

18 October 2022

The 6 finalists of the election “Starter with impact Eastern Netherlands 2022” have been announced and Radboudumc’s Aiosyn is one of them.

Aiosyn and Radboudumc are the first in the Netherlands to implement AI in the clinical pathology workflow Digital pathology slides will be screened with a quality control algorithm

4 April 2022 Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboudumc, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides.

LUMO Labs and Oost NL invest in Aiosyn Investment accelerates development of artificial intelligence platform to improve diagnostics

7 February 2022 Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. Oost NL is a co-investor.

Artificial intelligence as a digital colleague improves prostate cancer diagnosis Computer outperforms pathologists, but together they are even better

14 January 2022

Aiosyn is awarded the NWO Take Off Phase II grant

23 December 2021 Aiosyn, a Radboudumc spin-off company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council).

Aiosyn has been selected for Techleap's Pole Position Program

28 October 2021 This program focuses on helping 10 ambitious companies within the medical field to reach the scaleup growth phase.

New start-up Patholyt will bring AI research into pathology diagnostics

21 September 2021 Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.

What we do

spin-off companies
contact
news